Use of psychotropic drugs for neuropsychiatric symptoms in patients hospitalized with COVID-19
DOI:
https://doi.org/10.24265/horizmed.2021.v21n2.13Keywords:
Psychotropic drugs, Hospitalization, Coronavirus, Coronavirus infectionsAbstract
COVID-19 pandemic is the current global health crisis that, to date, has claimed thousands of lives in most countries. Since the beginning of 2020, the epidemiological and clinical behavior of the SARS-CoV-2, as well as proposals for therapeutic schemes that address the elimination of this virus per se and its complications at the systemic level, have been studied. However, neuropsychiatric symptoms also occur in patients hospitalized for this infection, so pharmacological management requires special considerations at the time of prescription. The most common neuropsychiatric symptoms secondary to COVID-19 infection are anxiety, insomnia, depressed mood, delirium and agitation. The choice of psychotropic drugs requires to be based on the principle of not generating more harm, and assessing the risk-benefit, pharmacological profile, possible interactions and previous medical conditions of the patient.
Downloads
References
Velavan TP, Meyer CG. The COVID-19 epidemic. Trop Med Int Health. 2020; 25(3): 278-80.
Zhang L, Liu Y. Potential interventions for novel coronavirus in China: Uso de psicofármacos para síntomas neuropsiquiátricos en pacientes hospitalizados con COVID-19 a systematic review. J Med Virol. 2020; 92(5): 479-90.
Gobierno del Estado Peruano. Coronavirus en el Perú: casos confirmados [Internet]. Lima; 2020. Disponible en: https://www.gob.pe/
Caly L, Druce JD, Catton MG, Jans DA, Wagstaff KM. The FDA approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro. Antiviral Res. 2020; 178: 104787.
Choudhary R, Sharma AK. Potential use of hydroxychloroquine, ivermectin and azithromycin drugs in fighting COVID-19: trends, scope and relevance. New Microbes New Infect. 2020; 35: 100684.
Mehra MR, Desai SS, Ruschitzka F, Patel AN. Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis. Lancet. 2020; S0140-6736(20): 31180-6.
Sanders JM, Monogue ML, Jodlowski TZ, Cutrell JB. Pharmacologic treatments for Coronavirus Disease 2019 (COVID-19): a review. JAMA. 2020; 323(18): 1824-36.
Zhai P, Ding Y, Wu X, Long J, Zhong Y, Li Y. The epidemiology, diagnosis and treatment of COVID-19. Int J Antimicrob Agents. 2020; 55(5): 105955.
Rogers JP, Chesney E, Oliver D, Pollak TA, McGuire P, Fusar-Poli P, et al. Psychiatric and neuropsychiatric presentations associated with severe coronavirus infections: a systematic review and meta-analysis with comparison to the COVID-19 pandemic. Lancet Psychiatry. 2020; 7(7): 611-27.
Guo Q, Zheng Y, Shi J, Wang J, Li G, Li C, et al. Immediate psychological distress in quarantined patients with COVID-19 and its association with peripheral inflammation: a mixed-method study. Brain Behav Immun. 2020; 88: 17-27.
Lovell N, Maddocks M, Etkind SN, Taylor K, Carey I, Vora V, et al. Characteristics, symptom management and outcomes of 101 patients with COVID-19 referred for hospital palliative care. J Pain Symptom Manage. 2020; S0885-3924(20): 30211-6.
Liguori C, Pierantozzi M, Spanetta M, Sarmati L, Cesta N, Iannetta M, et al. Subjective neurological symptoms frequently occur in patients with SARS-CoV2 infection. Brain Behav Immun. 2020; 88: 11-6.
Singh JA, Beg S, Lopez-Olivo MA. Tocilizumab for rheumatoid arthritis: a Cochrane systematic review. J Rheumatol. 2011; 38(1): 10-20.
Harrold LR, John A, Reed GW, Haselkorn T, Karki C, Li Y, et al. Impact of Tocilizumab monotherapy on clinical and patient-reported quality of-life outcomes in patients with rheumatoid arthritis. Rheumatol Ther. 2017; 4(2): 405-17.
Abers MS, Shandera WX, Kass JS. Neurological and psychiatric adverse effects of antiretroviral drugs. CNS Drugs. 2014; 28(2): 131-45.
Ginsberg DL. Azithromycin-induced psychotic depression and catatonia. Prim Psychiatry. 2006; 13(5): 22-6.
Dubovsky AN, Arvikar S, Stern TA, Axelrod L. The neuropsychiatric complications of glucocorticoid use: steroid psychosis revisited. Psychosomatics. 2012; 53(2): 103-15.
National Institute for Health and Care Excellence (NICE) in collaboration with NHS England and NHS Improvement. Managing COVID-19 symptoms (including at the end of life) in the community: summary of NICE guidelines. BMJ. 2020; 369: m1461.
Esteve Arríen A, Aguera Ortiz L, Manzano Palomo S. Manejo farmacológico de trastornos psicóticos en personas mayores con tratamiento de la infección por COVID19: interacciones y recomendaciones terapéuticas [Internet]. España; 2020. Disponible en:https://www.fesemi.org/sites/default/files/documentos/19.pdf
Khawam E, Khouli M, Pozuelo L. Treating acute anxiety in patients with Covid-19. Cleve Clin J Med. 2020.
University of Liverpool. Interactions with experimental COVID-19 Therapies [Internet]. 2020. Disponible en: https://www.covid19- druginteractions.org/
MedScape. Drug Interaction Checker [Internet]. 2020. Disponible en: https://reference.medscape.com/drug-interactionchecker
Huremović D. Psychiatry of Pandemics: a mental health response to infection outbreak. Springer Nature: Switzerland; 2019.
Zhang R, Wang X, Ni L, Di X, Ma B, Niu S, et al. COVID-19: melatonin as a potential adjuvant treatment. Life Sci. 2020; 250: 117583.
Zhang K, Zhou X, Liu H, Hashimoto K. Treatment concerns for psychiatric symptoms in patients with COVID-19 with or without psychiatric disorders. Br J Psychiatry. 2020; 217(1): 351.
Lewis SR, Pritchard MW, Schofield-Robinson OJ, Alderson P, Smith AF. Melatonin for the promotion of sleep in adults in the intensive care unit. Cochrane Database Syst Rev. 2018; 5(5): CD012455.
Anttila SAK, Leinonen EVJ. A review of the pharmacological and clinical profile of mirtazapine. CNS Drug Rev. 2001; 7(3): 249-64.
Luykx JJ, Van Veen SMP, Risselada A, Naarding P, Tijdink JK, Vinkers CH. Safe and informed prescribing of psychotropic medication during the COVID-19 pandemic. Br J Psychiatry. 2020; 217(3): 471-4.
Livingston RL, Zucker DK, Isenberg K, Wetzel RD. Tricyclic antidepressants and delirium. J Clin Psychiatry. 1983; 44(5): 173-6.
Kotfis K, Williams-Roberson S, Wilson JE, Dabrowski W, Pun BT, Ely EW. COVID-19: ICU delirium management during SARS-CoV-2 pandemic. Crit Care. 2020; 24(1): 176.
Baller EB, Hogan CS, Fusunyan MA, Ivkovic A, Luccarelli JW, Madva E, et al. Neurocovid: pharmacological recommendations for delirium associated with COVID-19. Psychosomatics. 2020.
Manjunatha N, Naveen Kumar C, Bada Math S. Mental health in the times of COVID-19 pandemic: Guidance for general medical and specialised mental health care settings. National Department of Psychiatry National Institute of Mental Health & Neurosciences (NIMHANS). 2020.
Jernigan MG, Kipp GM, Rather A, Jenkins MT, Chung AM. Clinical implications and management of drug-drug interactions between antiretroviral agents and psychotropic medications. Ment Health Clin. 2013; 2(9): 274-85.
Bilbul M, Paparone P, Kim AM, Mutalik S, Ernst CL. Psychopharmacology of COVID-19. Psychosomatics. 2020.
Published
How to Cite
Issue
Section
License
Copyright (c) 2021 Horizonte Médico (Lima)
This work is licensed under a Creative Commons Attribution 4.0 International License.
Horizonte Médico (Lima) (Horiz. Med.) journal’s research outputs are published free of charge and are freely available to download under the open access model, aimed at disseminating works and experiences developed in biomedical and public health areas, both nationally and internationally, and promoting research in the different fields of human medicine. All manuscripts accepted and published in the journal are distributed free of charge under the terms of a Creative Commons license – Attribution 4.0 International (CC BY 4.0).
